Covid-19 Impact Analysis Single-use Bioprocessing Market

Many pharmaceutical companies are rapidly developing vaccines in response to the novel coronavirus pandemic. For example, Moderna Therapeutics has a messenger RNA in Phase I trials, Inovio Pharmaceuticals’ has a DNA vaccine that has entered human trials, and Novavax is developing a vaccine based on its recombinant protein nanoparticle platform. The clinical and commercial manufacturing platforms will be largely supported by single-use equipment and systems. In the race to develop a vaccine against the coronavirus, many leading manufacturers of single-use bioreactors are currently working with companies that have a vaccine in development or already in the clinical test. For instance, Sartorius has supported CanSino Biologics Inc. and Maj. Gen. Chen Wei’s team at the Institute of Bioengineering at the Academy of Military Medical Sciences in China in their development of the first vaccine candidate against the novel coronavirus SARS-CoV-2 to enter clinical trials. This, in a way, has led to a positive impact on the single-use bioprocessing market.

In September 2020, ABEC announced it is supporting Serum Institute of India, Ltd. (SIIPL) in Pune, India by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax’ COVID-19 vaccine candidate, NVX‑CoV2373. Serum Institute, the world’s largest vaccine manufacturer by several doses, will utilize ABEC’s single-use technologies to advance a global supply of NVX‑CoV2373 throughout India and low- and middle-income countries.

However, Single-use Technology (SUT) has become a leading technology in pre-commercial manufacturing, including preclinical and clinical scale. Thus, drug discovery using SUT has become a major focus for the management of the pandemic. For instance, most COVID-19 vaccine research is based on single-use technologies. These efforts involve the use of novel approaches, such as mRNA and DNA technologies. Amid the COVID-19 pandemic, the health systems of countries are rapidly investing in research and development to combat the virus. To screen SARS-CoV-2 against a library of 50,000 compounds, it is necessary to use a single-use bioreactor for flexibility and speed, while keeping the total operating expenditure to a minimum.

For instance, in India, the Vaccine Task Force (VTF) set up by the Prime Minister’s Office (PMO) for focused research on coronavirus vaccines has allowed research institutions and laboratories to use patient samples for research and development (R&D) purposes. The government has framed detailed guidelines for sharing bio-specimen and data for such research among institutions. In September 2019, ABEC Inc. launched a single-use bioreactor system with a working volume of 6,000 L three times that of the industry’s standard upper limit. Single-use bioprocessing is crucial during COVID-19 and thus creates several growth opportunities. The United States is the most COVID-affected country in the world. The supply chain of products was highly impacted in this country. Initially, there is a decline in demand for single-use bioprocessing products which has negatively impacted the overall market growth. However, with the growing awareness regarding the importance as well as benefits of single-use bioprocessing technologies, the demand for the same will gradually increase in the forecast period. In addition, the U.S government is investing enormously in the development of vaccines, drugs, and diagnostic tests for the treatment of COVID-19, which is likely to drive the market for single-use bioreactors and thus ultimately drive the overall market growth. In March 2020, the government of Canada announced CAD 275 million (EUR 179 million) for the R&D activities related to antivirals, diagnostics, vaccines, and clinical trials for COVID-19. In addition in April 2020, Moderna Inc. received USD 483 million from the government of the United States, for the development of the vaccine against COVID-19. Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in the trial, the public and private sectors are anticipated to work in unison for the foreseeable period until a vaccine is developed for Covid-19. 

The demand for single-use technology has increased in recent years and, with the global need for mass manufacturing of a COVID-19 vaccine, there is even more pressure on the existing supply chain. In January 2021, Pall Corporation invested $114 million to increase global production capacity for single-use bioprocessing systems in response to COVID-19-related demand. The firm will add capacity at its facilities in Medemblik in the Netherlands, Hoegaarden in Belgium, Bad Kreuznach in Germany, Ilfracombe and Newquay in the UK, Fajardo in Puerto Rico, and Pensacola in the US. The investment is in keeping with recent statements made by Pall’s parent company Danaher. In October, the firm said Pall and its other bioprocessing tech unit Cytiva had secured over $1 billion in COVID-19-related orders. The emergence of COVID-19, a pandemic unleashed by the SARS-CoV-2 virus, caused a rapid and unexpected evolution in the industry over the last year. As the industry has moved swiftly from research to the production of new vaccines, the importance of system and raw material characterization has been magnified. Several technological developments are expected as a result of COVID-19. Efforts at the University of Queensland to develop a COVID-19 vaccine are receiving help from GE-Cytiva, which plans to develop a prototype affinity resin to support the COVID-19 vaccine candidate. MilliporeSigma's recent collaboration efforts with the Jenner Institute, Oxford, U.K., have led to their development of a rapid, scalable platform using disposable technologies for the institute's adenovirus platform. 

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com